Table 2.
Ongoing clinical trials in HNSCC.
| Immune Checkpoint Blocker Trials in Metastatic HNSCC | |||
|---|---|---|---|
| Study Name | Phase | NCT | Treatment Regimen |
| KEYNOTE B10 | 4 | NCT04489888 | Pembrolizumab + Carboplatin + Paclitaxel |
| LEAP-10 | 3 | NCT04199104 | Pembrolizumab vs. Pembrolizumab + Lenvatinib |
| 1 | NCT03498378 | Avelumab + Palbociclib + Cetuximab | |
| 1 and 2 | NCT03650764 | Pembrolizumab + Ramucirumab | |
| 1 and 2 | NCT03655444 | Nivolumab + Abemaciclib | |
| 2 | NCT04220866 | Intratumoral MK-1454 + Pembrolizumab vs. Pembrolizumab | |
| 1b/2 | NCT04193293 | Duvelisib + Pembrolizumab | |
| Vaccine and Cellular Therapy trials in metastatic HNSCC | |||
| 2 | NCT04369937 | ISA101b + Pembrolizumab + Cisplatin chemo RT | |
| 1 | NCT04290546 | CIML NK cells + IL-14 ± Ipilimumab | |
| 2 | NCT03083873 | Autologous TIL (LN-145/LN-145-S1) | |
| 1 | NCT03247309 | TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101) (ACTengine) | |
| 1 | NCT03912831 | HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01 + Subjects | |